2017-08-01T18:25:01+03:00[Europe/Moscow] en true Ledipasvir/sofosbuvir, Ledipasvir, Deleobuvir, Ombitasvir, Velpatasvir, Velpatasvir/sofosbuvir, Daclatasvir, Ravidasvir, Odalasvir, Sofosbuvir/daclatasvir, Samatasvir flashcards
NS5A inhibitors

NS5A inhibitors

Customize
collection saved
Share
Long Term Learning Spaced Repetition
Add to Long Term Learning Desk
Fast learning Repeat this set of flashcards
Preview Test Spell
Play
Match
Review
  • Ledipasvir/sofosbuvir
    Ledipasvir/sofosbuvir (trade name Harvoni) is a two-drug combination for the treatment of hepatitis C.
  • Ledipasvir
    Ledipasvir (formerly GS-5885) is a drug for the treatment of hepatitis C that was developed by Gilead Sciences.
  • Deleobuvir
    Deleobuvir (formerly BI 207127) was an experimental drug for the treatment of hepatitis C.
  • Ombitasvir
    Ombitasvir is an antiviral drug for the treatment of hepatitis C virus (HCV) infection.
  • Velpatasvir
    Velpatasvir is an inhibitor of NS5A used together with sofosbuvir in the treatment of hepatitis C infection of all six major genotypes.
  • Velpatasvir/sofosbuvir
    Velpatasvir/sofosbuvir (trade name Epclusa) is a two-drug combination for the treatment of hepatitis C.
  • Daclatasvir
    Daclatasvir (trade name Daklinza) is a drug for the treatment of hepatitis C (HCV).
  • Ravidasvir
    Ravidasvir (PPI-668) is an investigational NS5A inhibitor in clinical trials for chronic hepatitis C genotype 4.
  • Odalasvir
    Odalasvir (INN, previously known as ACH-3102) is an investigational new drug in development for the treatment of hepatitis C.
  • Sofosbuvir/daclatasvir
    Daclatasvir/sofosbuvir (trade name Darvoni) is a two-drug combination for the treatment of hepatitis C.
  • Samatasvir
    Samatasvir (IDX-719) is an experimental drug for the treatment of hepatitis C.